ASH 2023 | Impact of pre-transplant MRD status on disease outcomes in patients with multiple myeloma
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a retrospective, single-center study of patients with multiple myeloma (MM) which investigated the impact of measurable residual disease (MRD) status on outcomes following autologous hematopoietic cell transplantation (autoSCT). The study showed that patients with MRD positivity prior to autoSCT had a lower complete response rate and shorter progression-free survival, likely due to having higher risk disease. Dr Qazilbash notes that prospective studies are needed to validate these findings further but that MRD negativity is likely a robust prognostic factor for transplantation outcomes in MM. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Bioline
Research Funding: Amgen, Janssen, Angiocrine, NexImmune
